RSV

Ziresovir (RO-0529) is a respiratory syncytial virus fusion protein (RSV F) inhibitor that inhibits RSV activity and can be used in the study of syncytial virus sensing.

Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV).

Enzaplatovir (BTA-585) is an orally available fusion inhibitor with antiviral activity for the study of respiratory syncytial virus infections and coronavirus disease (COVID-19) infections.

Totrombopag (SB559448) is a candidate compound for action on RSV polymerase.

Roflumilast (APTA 2217) is an orally available, long-acting inhibitor of phosphodiesterase (PDE) type 4 (PDE4), with anti-inflammatory and potential antineoplastic activities. Upon administration, roflumilast and its active metabolite roflumilast N-oxide selectively and competitively bind to and inhibit PDE4, which leads to an increase of both intracellular levels of cyclic-3', 5'-adenosine monophosphate (cAMP) and cAMP-mediated signaling.

Nirsevimab (MEDI8897) is a recombinant human respiratory syncytial virus (RSV) monoclonal antibody with a modified Fc region, efficiently targeting RSV-B with a Kd value of 1.5 nM, and can be used to prevent RSV infection.

Amentoflavone (3',8''-Biapigenin), as a potent inhibitor of CYP3A4 and CYP2C9, can interact with many other medications. CYP3A4 and CYP2C9 are proteins used for drug metabolism in the body. Amentoflavone also is an inhibitor of human cathepsin B. It has antimalarial activity in trials significant affinities towards the Delta-1, kappa opioid receptors (as an antagonist) and binds to benzodiazepine receptors. Amentoflavone may be a potential lead for a new type of anti-inflammatory agents having the dual inhibitory activity of group II phospholipase A2 and cyclooxygenase. Amentoflavone and quercetin differentially exerted suppression of PGE2 biosynthesis via downregulation of COX-2/iNOS expression.

Ribavirin (Tribavirin) is a synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses.

Clesrovimab (MK1654) is an anti-respiratory syncytial virus protein F human monoclonal antibody for the prevention and treatment of respiratory syncytial virus infections.

EIDD-2749 (4'-FlU), a ribonucleoside analog, is an orally available RdRp inhibitor with spectroscopic antiviral activity that interrupts the replication of respiratory syncytial virus and SARS-CoV-2.EIDD-2749 attenuates lethal infections of pandemic human and highly pathogenic avian influenza viruses.

Cyclopiazonic acid (CPA) is a neurotoxic secondary metabolite (SM) made by A. flavus. Cyclopiazonic acid (CPA) is an endoplasmic reticulum calcium ATPase (Ca2+ATPase; SERCA)nanomolar inhibitor and a potent inducer of cell death in plants.

VV116 is a selective and orally active nucleoside antiviral agent against respiratory syncytial virus and SARS-CoV-2 infection.[1]

TNM001 is an anti-RSV fully humanized monoclonal antibody for the study of lower respiratory tract disease due to RSV infection.

Presatovir (GS-5806) (GS-5806) is a novel, orally bioavailable RSV fusion inhibitor (mean EC50: 0.43 nM).

Ac-CoA Synthase Inhibitor1 (ACSS2 inhibitor) is the most potent and specific inhibitor of acetate-dependent acetyl-CoA synthetase 2 (ACSS2).

Suptavumab (REGN2222) is a human monoclonal antibody that neutralizes conserved epitopes on subtypes A and B of RSV, making it useful for studying RSV infections and the respiratory system.

Sisunatovir hydrochloride (RV521 HCl) is an orally available inhibitor of the RSV-F protein that has exhibited potent efficacy against a panel of clinical isolates of RSV-A and RSV-B viruses in vitro (IC50 = 1.4 nM for RSV-A, IC50 = 1.0 nM for RSV-B).

Rilematovir (JNJ-678) is an inhibitor of fusion protein with antiviral activity and low cytotoxicity. Rilematovir can be used in studies about respiratory syncytial virus treatment.

RSV604 ((S)-1-(2-Fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea) is an inhibitor of respiratory syncytial virus (RSV) that binds to RSV nucleoprotein (Kd = 1.31 μM)

BTA-9881 is a novel RSV fusion inhibitor with oral activity and antiviral activity for the study of respiratory syncytial virus infections.

Rostafuroxin (PST 2238) has been used in trials studying the treatment of Essential Hypertension.

ALS-8112 (ALS 008112) is a selective and potent inhibitor of respiratory syncytial virus (RSV) polymerase with an IC50 value of 0.02 μM. ALS-8112 exhibits antiviral activity and inhibits the RNA polymerase activity of the RSV L-P protein complex through RNA chain termination. virus infections.

Perflubron (Perfluorooctyl bromide) can be emulsified with egg phospholipids (EYP) and displays exceptionally fast excretion characteristics. Perflubron(1-Bromoheptadecafluorooctane; Heptadecafluorooctyl bromide; Perfluorooctyl bromide) is a contrast medium for magnetic resonance imaging and sonography.

TMC353121 is a respiratory syncytial virus (RSV) fusion inhibitor with anti-RSV activity that inhibits the production of the inflammatory cytokines TNF-α, IL-6, and IL-1β, as well as chemokines, KC, IP-10, MCP, and MIP1-α.